Elicera's strengths are based on a deep understanding of how cells and viruses can be genetically engineered to trigger a powerful immune response to cancer.
Di Yu, Head of Technical Operations and co-founder, tells more about Elicera in the film.
Uppsala University is currently sponsoring an ongoing clinical phase I/II-study with Elicera's oncolytic virus, ELC-100, in neuroendocrine tumors. In addition, a second clinical phase I/II-study with CAR T-cell therapy, ELC-301, in B-cell lymphoma, is under planning.
Oops! Something went wrong while submitting the form.
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our Integrity policy.
